摘要在患有精神分裂症或精神分裂症样精神障碍的门诊患者中进行一个多中心，非比较的公开标签试验，目的是评估长期使用喹硫平对这类患者性功能的影响。试验共纳入86例患者，其中82例进入意向治疗（intent to treat）样本。精神病相关的性功能障碍调查表总体记分从基线至试验观察终点呈进行性和显著性下降。进行意向治疗分析的患者中，仅只有从一开始就使用喹硫平治疗，
2Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year followup of mortality in patients with schizophrenia: a populationbased cohort study(FINll study) [J]. Lancet, 2009, 374 (9690) : 620-627.
3Mihaloponlos C, Harris M, Henry L, et al. Is early intervention in psychosis cost-effective over the long term [J] ? Sehizophr Bull, 2009, 35 (5): 909-918.
4Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome [J]. J Am Acad Child Adolesc Psychiatry, 2007, 46 (10): 1349-1356.
5Essali A, Al-Haj HN, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia [J]. Cochrane Database Syst Rev, 2009 (1): D59.
6Ciudad A, Haro J M, Alonso J, et al. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain [J]. Eur Psychiatry, 2008, 23 (1) : 1-7.
7Novick D, Haro JM, Suarez D, et al. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study [J]. Int Clin Psychopharmacol, 2008, 23 (4) : 203-208.
8Dossenbach M, Pecenak J, Szulc A, et al. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study [J]. J Clin Psychiatry, 2008, 69 (12) : 1901-1915.
9Lindstrom E, Eberhard J, Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome[J]. Acta Psychiatr Scand, 2007, 116 (Suppl 435) : S5-S16.
10Peuskens J, Olivares J M, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries [J]. Curr Med Res Opin, 2010, 26 (3) : 501-509.
